A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to FOLFIRI
Related studies linked through entity extraction aliases.
Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418)
- Status
- RECRUITING
- Phase
- PHASE3
A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.
- Status
- COMPLETED
- Phase
- PHASE2
Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC
- Status
- TERMINATED
- Phase
- PHASE2
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
- Status
- RECRUITING
- Phase
- PHASE1
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
- Status
- TERMINATED
- Phase
- PHASE1
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
- Status
- RECRUITING
- Phase
- PHASE1
Expanded Access of Onvansertib With FOLFIRI and Bevacizumab for the Second-Line Treatment of Participants With KRAS-Mutated Metastatic Colorectal Cancer
- Status
- NO_LONGER_AVAILABLE
- Phase
- N/A
Pressure Enabled Drug Delivery By Pancreatic Retrograde Venous Infusion For Advanced Pancreatic Carcinoma
- Status
- WITHDRAWN
- Phase
- PHASE1
Post-surgical Liquid Biopsy-guided Treatment of Stage III and High-risk Stage II Colon Cancer Patients: the PEGASUS Trial
- Status
- UNKNOWN
- Phase
- PHASE2
Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
OSE2101+FOLFIRI, or FOLFIRI Maintenance After FOLFIRINOX-based Induction Therapy in Advanced or Metastatic PDAC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers
- Status
- COMPLETED
- Phase
- PHASE1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- Status
- RECRUITING
- Phase
- PHASE1
A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE1
A Study to Assess Safety, Efficacy, Immunogenicity, PK of GC1118 With Combination Chemotherapy
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels
- Status
- TERMINATED
- Phase
- PHASE2
A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies
- Status
- COMPLETED
- Phase
- PHASE1